Abstract Triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer, accounts for approximately 15% of all cases. TNBC remains challenging due to a lack of effective treatment strategies, which significantly impacts patient survival outcomes. This study investigates a novel combination therapy using Docetaxel, a microtubule depolymerization inhibitor, and Tamoxifen, an estrogen receptor (ER) antagonist, targeting TNBC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Guiling
Contact Guiling, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack